Non-small-cell lung cancers with activating mutations in the epidermal growth factor receptor develop resistance to tyrosine kinase inhibitors by recruiting the MET receptor kinase to activate HER3 and the PI3K-Akt cell survival pathway.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers
BMC Cancer Open Access 16 October 2019
-
MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer
BMC Cancer Open Access 11 May 2009
-
Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
British Journal of Cancer Open Access 24 February 2009
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Engelman, J.A. et al. Science; published online 26 April 2007 (doi:10.1126/science.1141478).
Shah, N.P. et al. Cancer Cell 2, 117–125 (2002).
Daub, H., Specht, K. & Ullrich, A. Nat. Rev. Drug Discov. 3, 1001–1010 (2004).
Sharma, S.V., Bell, D.W., Settleman, J. & Haber, D.A. Nat. Rev. Cancer 7, 169–181 (2007).
Riely, G.J. et al. Clin. Cancer Res. 12, 839–844 (2006).
Pao, W. et al. PLoS Med. 2, e73 (2005).
Kobayashi, S. et al. N. Engl. J. Med. 352, 786–792 (2005).
Kosaka, T. et al. Clin. Cancer Res. 12, 5764–5769 (2006).
Balak, M.N. et al. Clin. Cancer Res. 12, 6494–6501 (2006).
Boccaccio, C. & Comoglio, P.M. Nat. Rev. Cancer 6, 637–645 (2006).
Engelman, J.A. et al. Proc. Natl. Acad. Sci. USA 102, 3788–3793 (2005).
Engelman, J.A. et al. J. Clin. Invest. 116, 2695–2706 (2006).
Ricci, C. et al. Cancer Res. 62, 5995–5998 (2002).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Arteaga, C. HER3 and mutant EGFR meet MET. Nat Med 13, 675–677 (2007). https://doi.org/10.1038/nm0607-675
Issue Date:
DOI: https://doi.org/10.1038/nm0607-675
This article is cited by
-
STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers
BMC Cancer (2019)
-
Molecular Classification of Gastric Adenocarcinoma: Translating New Insights from The Cancer Genome Atlas Research Network
Current Treatment Options in Oncology (2015)
-
Gastric cancer—molecular and clinical dimensions
Nature Reviews Clinical Oncology (2013)
-
Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer
Virchows Archiv (2013)
-
Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy
Acta Pharmacologica Sinica (2010)